Cell atrophy and loss in depression: Reversal by antidepressant treatment

Current Opinion in Cell Biology

Volumn 23, Issue 6, 2011, Pages 730-737

  Banasr, Mounira ^a   Dwyer, Jason M ^a   Duman, Ronald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; KETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; N METHYL DEXTRO ASPARTIC ACID; NEUROTROPHIC FACTOR; WNT PROTEIN;

APOPTOSIS; BRAIN ATROPHY; CELL COUNT; CELL GROWTH; CELL LOSS; CELL STRESS; CELL SURVIVAL; CHRONIC STRESS; DEPRESSION; EXCITOTOXICITY; GLIA CELL; NERVE CONDUCTION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ATROPHY; BRAIN; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; MOOD DISORDERS; NEUROGLIA; NEURONS;

ANIMALIA;

EID: 82555205300     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2011.09.002     Document Type: Review

References (84)

1. Kessler R., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R. The epidemiology of major depressive disorder: results from the national comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003, 289:3095-3105.
2. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
3. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
4. Trivedi M., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
5. Lucassen P.J., Heine V.M., Muller M.B., van der Beek E.M., Wiegant V.M., De Kloet E.R., Joels M., Fuchs E., Swaab D.F., Czeh B. Stress, depression and hippocampal apoptosis. CNS Neurol Disord Drug Targets 2006, 5:531-546.
6. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233.
7. Liu R.-J., Aghajanian G.K. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci U S A 2008, 105:359-364.
8. Radley J., Sisti H.M., Hao J., Rocher A.B., McCall T., Hof P.R., McEwen B.S., Morrison J.H. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience 2004, 125:1-6.
9. Radley J., Rocher A.B., Janssen W.G., Hof P.R., McEwen B.S., Morrison J.H. Reversibility of apical dendritic retraction in the rat medial prefrontal cortex following repeated stress. Exp Neurol 2005, 196:199-203.
10. Radley J., Rocher A.B., Miller M., Janssen W.G., Liton C., Hof P.R., McEwen B.S., Morrison J.H. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex 2006, 16:313-320.
11. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., Li X.Y., Aghajanian G., Duman R.S. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011, 69:754-761.
12. McEwen B. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007, 87:873-904.
13. Kim S., Webster M.J. Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2010, 15:326-336.
14. Muller H.K., Wegener G., Popoli M., Elfving B. Differential expression of synaptic proteins after chronic restraint stress in rat prefrontal cortex and hippocampus. Brain Res 2011, 1385:26-37.
15. Czeh B., Simon M., Schmelting B., Hiemke C., Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006, 31:1616-1626.
16. Banasr M., Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008, 64:863-870.
17. Rajkowska G., O'Dwyer G., Teleki Z., Stockmeier C.A., Miguel-Hidalgo J.J. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007, 32:471-482.
18. Maciag D., Hughes J., O'Dwyer G., Pride Y., Stockmeier C.A., Sanacora G., Rajkowska G. Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry 2010, 67:465-470.
19. Sanacora G. Cortical inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire?. Biol Psychiatry 2010, 67:397-398.
20. Sanacora G., Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 2007, 6:127-140.
21. Drew M., Hen R. Adult hippocampal neurogenesis as target for the treatment of depression. CNS Neurol Disord Drug Targets 2007, 6:205-218.
22. Banasr M., Duman R.S. Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol Disord Drug Targets 2007, 6:311-320.
23. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007, 10:1110-1115.
24. Snyder J.S., Soumier A., Brewer M., Pickel J., Cameron H.A. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011, 476:458-461.
25. Boldrini M., Underwood M.D., Hen R., Rosoklija G.B., Dwork A.J., John Mann J., Arango V. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009, 34:2376-2389.
26. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
27. McEwen B.S., Magarinos A.M. Stress effects on morphology and function of the hippocampus. Ann N Y Acad Sci 1997, 821:271-284.
28. Moghaddam B., Bolinao M.L., Stein-Behrens B., Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res 1994, 655:251-254.
29. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993, 60:1650-1657.
30. Zink M., Vollmayr B., Gebicke-Haerter P.J., Henn F.A. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 2010, 58:465-473.
31. Castren E., Voikar V., Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007, 7:18-21.
32. Duman R., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
33. Monteggia L. Elucidating the role of brain-derived neurotrophic factor in the brain. Am J Psychiatry 2007, 164:1790.
34. Chen Z.-Y., Jing D., Bath K.G., Leraci A., Khan T., Siao C.-J., Herrara D.G., Toth M., Yang C., McEwen B.S., et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006, 314:140-143.
35. Egan M., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
36. Liu R., Lee F.S., Li X.Y., Bambico F., Duman R.S. Aghajanian GK: BDNF Met allele decreases the density and function of spine/synapses in the prefrontal cortex and blocks synaptogenic and antidepressant effects of ketamine. Biological Psychiatry 2011, in press.
37. Duman C., Schlesinger L., Kodama M., Russell D.S., Duman R.S. A role for MAPK signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 2007, 61:661-670.
38. Gatt J., Nemeroff C.B., Dobson-Stone C., Pauyl R.H., Bryant R.A., Schofield P.R., Gordon E., Kemp A.H., Williams L.M. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009, 14:681-695.
39. Miyajima F., Ollier W., Mayes A., Jackson A., Thacker N., Rabbitt P., Pendleton N., Horan M., Payton A. Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav 2008, 7:411-417.
40. Nagel I., Chicherio C., Li S.C., von Oertzen T., Sander T., Villringer A., Heekeren H.R., Bäckman L., Lindenberger U. Human aging magnifies genetic effects on executive functioning and working memory. Front Hum Neurosci 2008, 2:1-8.
41. Kosten T.A., Galloway M.P., Duman R.S., Russell D.S., D'Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008, 33:1545-1558.
42. Silva R., Mesquita A.R., Bessa J., Sousa J.C., Sotiropoulos I., Leao P., Almeida O.F., Sousa N. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008, 152:656-669.
43. Maeng S., Hunsberger J.G., Pearson B., Yuan P., Wang Y., Wei Y., McCammon J., Schloesser R.J., Zhou R., Du J., et al. BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A 2008, 105:8766-8771.
44. Hunsberger J.G., Austin D.R., Chen G., Manji H.K. Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Res 2009, 1293:76-84.
45. Bachis A., Cruz M.I., Nosheny R.L., Mocchetti I. Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex. Neurosci Lett 2008, 442:104-108.
46. Bravo J.A., Diaz-Veliz G., Mora S., Ulloa J.L., Berthoud V.M., Morales P., Arancibia S., Fiedler J.L. Desipramine prevents stress-induced changes in depressive-like behavior and hippocampal markers of neuroprotection. Behav Pharmacol 2009, 20:273-285.
47. Liu Y., Ma S., Qu R. SCLM, total saponins extracted from Chaihu-jia-longgu-muli-tang, reduces chronic mild stress-induced apoptosis in the hippocampus in mice. Pharm Biol 2010, 48:840-848.
48. Malkesman O., Austin D.R., Tragon T., Henter I.D., Reed J.C., Pellecchia M., Chen G., Manji H.K. Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol Psychiatry 2011.
49. Chen F., Madsen T.M., Wegener G., Nyengaard J.R. Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression. Hippocampus 2010, 20:1376-1384.
50. Czeh B., Simon M., van der Hart M.G., Schmelting B., Hesselink M.B., Fuchs E. Chronic stress decreases the number of parvalbumin-immunoreactive interneurons in the hippocampus: prevention by treatment with a substance P receptor (NK1) antagonist. Neuropsychopharmacology 2005, 30:67-79.
51. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010, 15:501-511.
52. Koo J., Duman R.S. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Invest Drugs 2009, 10:664-671.
53. Krishnan V., Nestler E.J. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010, 167:1305-1320.
54. Schmidt H., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007, 18:391-418.
55. Fournier N., Duman R.S. Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res 2011, [Epub ahead of print].
56. Watanabe Y., Gould E., Daniels D.C., Cameron H., McEwen B.S. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 1992, 222:157-162.
57. Li C., Xu J.M., Liu D., Zhang J.Y., Dai R.P. Brain derived neurotrophic factor (BDNF) contributes to the pain hypersensitivity following surgical incision in the rats. Mol Pain 2008, 4:27.
58. Greene J., Banasr M., Duman R.S. VEGF signaling is required for the behavioral actions of 5-HT selective reuptake inhibitor antidepressants. Neuropsychopharmacology 2009, 34:2459-2468.
59. Warner-Schmidt J., Duman R.S. VEGF is an essential mediator of neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A 2007, 104:4647-4652.
60. Dwivedi Y., Rizavi H.S., Conley R.R., Pandey G.N. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol Psychiatry 2006, 11:86-98.
61. Dwivedi Y., Rizavi H.S., Teppen T., Sasaki N., Chen H., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Aberrant extracellular signal-regulated kinase (ERK) 5 signaling in hippocampus of suicide subjects. Neuropsychopharmacology 2007, 32:2338-2350.
62. Duric V., Banasr M., Licznerski P., Schmidt H., Stockmeier C., Simen A., Newton S.S., Duman R.S. Negative regulator of MAP kinase is increased in depression and is necessary and sufficient for depressive behavior. Nat Med 2010, 16:1328-1332.
63. Bachmann R.F., Schloesser R.J., Gould T.D., Manji H.K. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005, 32. 173-102.
64. Gould T., Einat H., Bhat R., Manji H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004, 7:387-390.
65. Okamoto H., Voleti B., Banasr M., Sarhan M., Duric V., Girgenti M.J., Dileone R.J., Newton S.S., Duman R.S. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry 2010, 68:521-527.
66. Kang H.J., Adams D.H., Simen A., Simen B.B., Rajkowska G., Stockmeier C.A., Overholser J.C., Meltzer H.Y., Jurjus G.J., Konick L.C., et al. Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci 2007, 27:13329-13340.
67. Omata N., Chiu C.T., Moya P.R., Leng Y., Wang Z., Hunsberger J.G., Leeds P., Chuang D.M. Lentivirally mediated GSK-3beta silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol 2011, 14:711-717.
68. Alvania R.S., Chen X., Ginty D.D. Calcium signals control Wnt-dependent dendrite growth. Neuron 2006, 50:813-815.
69. Wayman G.A., Impey S., Marks D., Saneyoshi T., Grant W.F., Derkach V., Soderling T.R. Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. Neuron 2006, 50:897-909.
70. Machado-Vieira R., Salvadore G., Diazgranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009, 123:143-150.
71. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
72. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
73. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
74. Larkin G.L., Beautrais A.L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011, 1-5.
75. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66:522-526.
76. Li N., Lee B.Y., Liu R.J., Banasr M., Dwyer J., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
77. Autry A., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., Kavalali E.T., Monteggia L.M. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 2011, [Epub ahead of print].
78. Hoeffer C.A., Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 2010, 33:67-75.
79. Jernigan C.S., Goswami D.B., Austin M.C., Iyo A.H., Chandran A., Stockmeier C.A., Karolewicz B. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011.
80. 11C]ABP688 PET and postmortem study. Am J Psychiatry 2011.
81. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:70-75.
82. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
83. aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010, 67:139-145.
84. Jourdi H., Hsu Y.T., Zhou M., Qin Q., Bi X., Baudry M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci 2009, 29:8688-8697.